Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue PADP Prior Auth Policy Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFlorida BluePolicy N/A

    Provider‑Administered Drug Program (PADP) — MRxM (Prime Therapeutics) management and prior authorization

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Florida Blue's PADP utilization management handled by Prime Therapeutics (MRxM) for a listed set of provider‑administered medications and the requirement that participating providers obtain prior authorization before drug administration. Applies to covered Florida Blue member products and specified places of service.

    Policy Summary
    PayerFlorida Blue
    PolicyProvider‑Administered Drug Program (PADP) — MRxM management and prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization from Prime Therapeutics (MRxM) for PADP‑listed drugs prior to administration when required by the member's benefit plan or provider contract.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    200+Listed codes/drugs
    Since July 2009Managed since
    Prior authorization requiredAuth required
    Most include eff datesEntries with dates
    MultiplePlaces of service

    Coverage Criteria

    General PADP prior authorization criteria

    Covered when ALL of the following are met:

    PADP prior auth required: Provider must obtain prior authorization from Prime Therapeutics Management (MRxM) for drugs included on the PADP Drug List prior to administration when the member's benefit plan or provider contract requires prior authorization.

    If prior authorization is not obtained, payment for the service may be denied and the member cannot be held responsible for denied charges.

    Applicable member products and places of service: The PADP prior authorization requirement applies for covered member products and places of service managed by MRxM (examples include BlueCare HMO, SimplyBlue, My Blue, BlueOptions, BlueSelect, BlueChoice, Medicare Part B Primary as specified, office, ambulatory infusion suite (AIS), other outpatient centers, home, and clinics).

    Medicare Advantage HMO & PPO effective 07/01/2021 are excluded from MRxM management per the PADP document.

    Code and documentation requirement: Providers must reference the exact HCPCS/J-code and corresponding drug name from the MRxM PADP list when requesting prior authorization or submitting claims to ensure correct management and benefits adjudication.
    Policy Summary
    PayerFlorida Blue
    PolicyProvider‑Administered Drug Program (PADP) — MRxM management and prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization from Prime Therapeutics (MRxM) for PADP‑listed drugs prior to administration when required by the member's benefit plan or provider contract.
    SourceLink
    On This Page
    Coverage CriteriaHCPCS / J-code List and Coding NotesProvider Actions and Prior Authorization ProcedurePlaces of Service and Billing ImplicationsStep Therapy Notes

    Each PADP HCPCS entry includes an effective date and termination date; providers should verify the PADP effective/termination dates for the date of service.

    Unclassified/unspecified HCPCS and billing note: Drugs billed using unclassified or unspecified HCPCS (for example J9999, J3590, J1599, A9699) included on the PADP Drug List are managed by MRxM and require prior authorization when applicable.

    Billing with C9399 (unspecified drug C-code) will not trigger MRxM authorizations; MRxM authorizations will not be applied when billing C9399. C-codes are only billable for specified drug services in the Hospital Outpatient setting.

    Providers that participate with Florida Blue Utilization Management Programs (PADP) must obtain prior authorization from Prime Therapeutics (MRxM) for drugs included on the PADP Drug List prior to administration when the member's benefit product or provider contract requires it. PADP has been managed by Prime Therapeutics (MRxM) since July 2009 and applies to the member products and places of service listed in the program; if prior authorization is not obtained, payment for that service will be denied and the member cannot be held responsible for the denied charges.

    Use the specific HCPCS/C code guidance in the PADP list when billing. C-codes are only billable for the specified drug services within the Hospital Outpatient setting; for all other places of service providers must bill using the corresponding unspecified or unclassified HCPCS (for example, J9999, J3590, J1599 or other unspecified HCPCS) until CMS assigns a permanent HCPCS. Note that drugs associated to J9999 are NQI accepted with C9399 and MRxM authorizations will not be applied when billing C9399.

    HCPCS / J-code List and Coding Notes

    PADP Listed HCPCS / J-codes (selected)HCPCSCovered
    J9024ATEZOLIZUMAB & HYALURONIDASE (TECENTRIQ HYBREZA)
    J9025AZACITIDINE (VIDAZA)
    J9026TARLATAMAB-DLLE (IMDELLTRA)
    J9028NOGAPENDEKIN ALFA INBAKICEPT-PMLN (ANKTIVA)
    J9029NADOFARAGENE FIRADENOVEC-VNCG (ADSTILADRIN)
    J9032BELINOSTAT (BELEODAQ)
    J9033BENDAMUSTINE (TREANDA)
    J9034BENDAKA / BENDEKA (BENDAMUSTINE)
    J9035BEVACIZUMAB (AVASTIN - oncology use)
    J9036BENDAMUSTINE HCL (BELRAPZO)
    1–10 of 19
    1/2
    Covered HCPCS / J-codes (partial)HCPCSCovered
    J9171DOCETAXEL (DOCEFREZ / TAXOTERE)
    J9172DOCETAXEL
    J9173DURVALUMAB (IMFINZI)
    J9176ELQTUZUMAB (EMPLICITI)
    J9177ENFORTUMAB VEDOTIN (PADCEV)
    Covered HCPCS / J-codes (partial)HCPCSCovered
    J9198GEMCITABINE HYDROCHLORIDE (INFUGEM)
    J9202GOSERELIN ACETATE (ZOLADEX)
    J9203GEMTUZUMAB-OZOGAMICIN (MYLOTARG)
    Covered HCPCS / J-codes (partial)HCPCSCovered
    J9227ISATUXIMAB-IRFC (SARCLISA)
    J9228IPILIMUMAB (YERVOY)
    J9229BESPONSA
    Covered HCPCS / J-codes (partial)HCPCSCovered
    J9301OBINUTUZUMAB (GAZYVA)
    J9302QFATUMUMAB (ARZERRA)
    J9303PANITUMUMAB (VECTIBIX)
    J9304PEMETREXED (PEMFEXY)
    Covered HCPCS / J-codes (continued, partial)HCPCSCovered
    J9316PERTUZUMAB_TRASTUZUMAB_and HYALURONIDASE (PHESGO)
    J9321EPCORITAMAB-BYSP (EPKINLY)
    J9325TALIMOGENE LAHERPAREPVEC (IMLYGIC)
    J9330TEMSIROLIMUS (TORISEL)
    J9332EFGARTIGIMOD ALFA-FCAB (VYVGART)
    J9333ROZANOLIXIZUMAB-NOLL (RYSTIGGO)
    J9347TREMELIMUMAB-ACTL (IMJUDO)
    J9348NAXITAMAB-GQGK (DANYELZA)
    Listed J-codes (partial)HCPCSCovered
    J9048BORTEZOMIB (alternate HCPCS effective 01/01/2023)
    Listed J-codes (continued)HCPCSCovered
    J9049BORTEZOMIB (alternate HCPCS effective 01/01/2023)
    J9055CETUXIMAB (ERBITUX)
    J9056BENDAMUSTINE HYDROCHLORIDE (VIVIMUSTA)
    J9061AMVANTAMAB-VMJW (RYBREVANT)
    More J-codesHCPCSCovered
    J9144DARATUMUMAB & HYALURONIDASE (DARZALEX FASPRO)
    J9145DARATUMUMAB (DARZALEX)
    J9161DENILEUKIN DIFTITOX-CXDL (LYMPHIR)
    J9179ERIBULIN (HALAVEN)
    J9198GEMCITABINE (INFUGEM)
    Additional J-codesHCPCSCovered
    J9161DENILEUKIN DIFTITOX-CXDL (LYMPHIR)
    J1307CROVALIMAB-AKKZ (PIASKY)
    J08Z0New HCPCS example (placeholder for specified agent)
    Q-codes and new HCPCS entriesHCPCSCovered
    Q5146TRASTUZUMAB-STRE (HERCESSI)
    Q5147AFLIBERCEPT-AYYH (PAVBLU)
    Q5148FILGRASTIMTXID (NYPOZI)
    Q5149AFLIBERCEPT-ABZV (ENZEEVU)
    Q5150AFLIBERCEPT-MRBB (AHZANTIVE)
    Q5151ECULIZUMAB-AAGH (EPYSQLI)
    Q5152ECULIZUMAB-AEEB (BKEMV)
    Listed specific Q/Q999 HCPCS codes in PADP listHCPCSCovered
    Q5146HERCESSI (TRASTUZUMAB-STRE)
    Q5147PAVBLU (AFLIBERCEPT-AYYH)
    Q5148NYPOZI (FILGRASTIMTXID)
    Q5149ENZEEVU (AFLIBERCEPT-ABZV)
    Q5150AHZANTIVE (AFLIBERCEPT-MRBB)
    Q5151EPYSQLI (ECULIZUMAB-AAGH)
    Q5152BKEMV (ECULIZUMAB-AEEB)
    Unclassified / Unlisted HCPCS and general billing notesHCPCS
    J9999Unclassified antineoplastic / NOC — used when CMS has not assigned a specific HCPCS; PADP manages drugs under J9999/J3590/J1599 etc.
    J3590Unclassified biologics — used for products pending specific HCPCS assignment
    C9399Not otherwise classified drug — NQI accepted for drugs associated to J9999; authorizations not applied when billing C9399

    Provider Actions and Prior Authorization Procedure

    Prior Authorization

    Prior Authorization Required

    Florida Blue has contracted with Prime Therapeutics Management MPS division (formerly Magellan Rx Management / MRxM ICORE) to manage the Provider-Administered Drug Program (PADP). Providers must obtain prior authorization from MRxM for PADP-listed drugs when the member product/benefit requires prior authorization. If prior authorization is not obtained for an applicable PADP drug, payment may be denied and the Member cannot be held responsible for denied charges.

    • Member products requiring prior authorization include: BlueCare HMO (Group & Individual), SimplyBlue, My Blue, BlueSelect, BlueOptions ACA CE Plans (Group & Individual), BlueChoice Group ACA/CE Plans, and other member arrangements listed in the PADP/Medical and Specialty Drug UM lists.
    • Providers participating with Florida Blue Utilization Management Programs (PADP) must obtain prior authorization for PADP drugs prior to administration.
    • Voluntary Predetermination of Select Services (VPSS) is available for member/provider arrangements that do not require prior authorization; VPSS for PADP drugs is reviewed by MRxM.
    • When a member product requires a referral or separate prior authorization for home nursing or specialist referral, those will be reviewed separately by Florida Blue.
    Billing Rule

    Use Listed HCPCS/J-code

    Use the HCPCS / J-code listed in the PADP Drug List when submitting claims or prior authorization requests. When a drug has been assigned a specific HCPCS (including J-codes), that HCPCS must be used for billing and for MRxM management.

    • Use the listed HCPCS/J-code on claims and prior authorization submissions for PADP drugs.
    • If a drug has been assigned a new HCPCS, the HCPCS will be included in the PADP Drug List and managed by MRxM going forward.
    • C-codes are only billable for the specified drug services within the Hospital Outpatient setting; other settings must use the corresponding unspecified drug HCPCS until a listed HCPCS is assigned by CMS.
    Note

    Codes Managed by MRxM PADP (partial list)

    Inclusion of a HCPCS/J-code in the PADP Drug List indicates the product is managed by MRxM and prior authorization applies per member benefit requirements. The PADP listing includes an effective date and, where applicable, a termination date for each code — providers should reference those PADP effective/termination dates when determining management and authorization applicability.

    • Inclusion in the PADP list implies MRxM management and that prior authorization requirements apply.
    • Each PADP entry includes PADP EFF DATE and TERMDATE (if applicable) — verify these dates when checking whether a code is managed.
    • The PADP list contains a partial set of HCPCS/J-codes (examples include J1568, J1599*, J1602, J1627, J1628, J2506, J2507, J9047, J9048, J9061, J9118, J9144, Q2049, Q5101, Q5103, etc.).
    Documentation Required

    Authorization Interaction with Unspecified Drug Code C9399

    Some PADP entries use unspecified/unclassified HCPCS (for example J1599*, J9999*, J3590*). When drugs are billed using an unspecified code such as C9399 or certain J-/unclassified codes, MRxM authorizations may not be applied. Specifically, drugs associated to J9999 are noted as NQI accepted with C9399 and MRxM authorizations will not be applied when billing C9399.

    • When a drug is assigned to a specific HCPCS, it will be managed through MRxM; however, billing with unspecified codes (e.g., C9399) can prevent MRxM authorization from applying.
    • Drugs associated with J9999 are NQI accepted with C9399; MRxM authorizations will not be applied when billing C9399.
    • Providers must avoid using C9399 when a specific PADP HCPCS exists and should bill the assigned HCPCS to ensure MRxM prior authorization is applied.
    Step Therapy

    Step / Addition Management — Periodic Updates

    Step therapy, additions, and periodic updates: the PADP drug list is updated periodically. Additions to the PADP Drug List will be made periodically and may change which products require MRxM prior authorization. Providers should monitor PADP updates for new HCPCS assignments and step/addition management changes.

    • PADP additions and updates are performed periodically — newly assigned HCPCS will be added to the PADP list and managed by MRxM on their PADP EFF DATE.
    • Step therapy rules and specific step/addition details are maintained in PADP update notices or companion step therapy documents; check the PADP and Medical/Specialty Drug UM lists for current requirements.
    • Failure to follow updated step therapy or prior authorization processes may result in claim denials.

    Places of Service and Billing Implications

    Documentation Required

    PADP applies to listed places of service

    PADP management and prior authorization requirements apply when administration occurs in the listed places of service, including outpatient (on- and off-campus), office, ambulatory infusion suite (AIS), other outpatient centers, home, and clinics.

    • Verify place of service to determine PADP applicability and prior authorization routing.
    Billing Rule

    C-code billing limited to Hospital Outpatient setting

    C-codes are only billable for the specified drug services within the Hospital Outpatient setting; all other settings must be billed with the corresponding unspecified drug HCPCS until CMS assigns a listed HCPCS.

    • Do not use C-codes outside Hospital Outpatient for PADP drugs; use unspecified HCPCS (e.g., J9999/J3590) instead.

    Step Therapy Notes

    Step Therapy

    Step therapy not provided in this segment

    No step therapy information is specified in this PADP segment; providers should consult separate step therapy or Medical and Specialty Drug UM List resources if step requirements are needed.